Member Info for HOMER1234

Well someone bought £17k this morning.

Share price at a near all-time low.

It doesn't bring out bad news. It's just that nobody ever hears of it.

I am beginning to hope we get bought out as it will stop me from looking at this terrible-run company.

He might own more than 9% as it certainly took a long time to declare his holding.

Follow the money. I would expect a collaboration RNS in the near future. Will buy some more as this is big news. IMHO.

Well, I was considering topping up but this could go 30% either way. Shambles.

He's the American guy.

We are delighted to share the release of our latest scientific paper outlining a drug delivery strategy poised to redefine cancer therapy.

Here's an overview of what we've uncovered:

Addressing treatment challenges: Current approaches to cancer treatment are limited by high general toxicity and low efficacy, driving a pressing need for novel, innovative treatment strategies.

Unlocking potential with combination therapy: Drawing inspiration from successful combination treatments in other medical fields, combination approaches could hold tremendous promise in enhancing treatment efficacy and overcoming resistance mechanisms.

Focusing on siRNA delivery: With small interfering RNA (siRNA) becoming increasingly used in the development of therapeutics, it is critical that these nucleic acids are delivered to tumours safely and efficiently. Dual delivery of siRNA, with or without a relevant, additional, small-molecule therapeutic agent, may be the key to unlocking a new era of treatment efficiency in cancer.

Innovative delivery platform: Departing from conventional delivery methods, mesoporous silica nanoparticles (MSNs) offer a potential solution for precise drug delivery. A novel silica nanoparticle delivery system has been developed (Nuvec®, N4 Pharma) specifically to safely and efficiently deliver siRNAs to tumours to inhibit multiple tumour growth factor pathway. Novel delivery systems that allow for double or even multiple siRNA loading will be critical to the success of future siRNA-based cancer therapeutics.

We believe this drug delivery approach provides a clear strategy to pave the way for more targeted and efficient first-line cancer therapy. A solid delivery platform will be pivotal in allowing developers to realise their goals.

It does say they will present to potential partners.

This is the news we need. It's another big step but it's not going to get the investors in.

Nigel must realize this. The next raise won't be funded by us it will be by these partners. Nigel already mentioned this.

The clock is ticking and it a very depressing to look at the price after the recent run. Were back where we started from.

Patents in all these countries don't mean a lot until we have something commercially viable.

No idea who would sell at this level. But again this is being pushed down for another rinse and repeat.

Thank you for your honest post. BMN has become another AIM company run by idiots.

It's a great report. I just don't think we promote this enough.

It is out of their hands. But very poor from SPR.

Guess you have sold out and coming back with the negative vibes. Patent for India is such terrible news.

IG is not an institutional shareholder. lol

Why would they need to raise? It was already confirmed in the investor's call that they would not need to.

They would look at other avenues.

Also, the last placement has not even been finished being sold in the market. Hence the large trades.

But a lot of people who invest don't even listen to the presentations.

Well, it bounced from 1.31. Looks like we're being played like a fiddle.

That guy from the Dhaka Tribune which is everybody's first stop for investor advice is talking nonsense. It will be far quicker than that.

Yes but as I said last week some of the placement of 35 million shares at 1p would be sold in market. Price has not been above 1p since it was announced. But I agree people have sold at a profit. But I feel were move up to the next level shortly.

Things are coming together here and the dots are being joined. One of the issues being discussed is funding. N4 has already stated that Nanogenics could be funded by third parties. To this end, it is interesting that Dr Simon Newman the Chief Scientific Officer of Nanogenics will take up the same role at the Brain Tumour Charity next month whilst continuing that role at Nanogenics. Interesting because the Brain Tumour Charity is both heavily involved in tumour research itself but more importantly is a major financier of tumour research both directly and through third parties. To have the Nanogenics CSO acting in the interests of Nanogenics/Nuvec could be very advantageous.

Wow nice buy. 👏